Optimal targeting of the mTORC1 kinase in human cancer
- 30 April 2009
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Cell Biology
- Vol. 21 (2), 219-229
- https://doi.org/10.1016/j.ceb.2009.01.016
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatmentDrug Resistance Updates, 2008
- Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphomaCancer, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2008
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004